Carla Casulo

Also affiliated with University of Rochester

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma”.

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

New England Journal of Medicine(2024)10.1056/nejmoa2405888

N/A

3.4DataRank · unranked

211 citations

Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens +42 more

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102959

N/A

0.465DataRank · unranked

9 citations

Michael T. Brady, Myla Strawderman, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen +13 more

The POD24 challenge: where do we go from here for early progressors?

Hematology(2024)10.1182/hematology.2024000662

N/A

0DataRank · unranked

8 citations

Carla Casulo, Patrizia Mondello

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

Journal of Clinical Oncology(2025)10.1200/jco-25-00892

N/A

0DataRank · unranked

1 citations

Vít Procházka, Tarec Christoffer El‐Galaly, Christopher R. Flowers, Diego Villa, Emmanuel Bachy +43 more

233 | S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24)

Hematological Oncology(2025)10.1002/hon.70094_233

N/A

0DataRank · unranked

0 citations

H. Li, Heiko Schöder, Alex F. Herrera, Richard Burack, Brian K. Link +10 more